Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries

References

• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43: 738–44.
   PubMed Web of Science ®Google Scholar
• Fluit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005;49:1636–8.
   PubMed Web of Science ®Google Scholar
• Hirata T, Saito A, Nishino K, Tamura N, Yamaguchi A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004;48:2179–84.
   PubMed Web of Science ®Google Scholar
• European Antimicrobial Resistance Surveillance Network (EARSS-Net). Available at: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx (accessed 16 December 2010).
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: http://www.eucast.org (accessed 16 December 2010).
   Google Scholar
• Bolmstrom A, Karlsson A, Engelhardt A, Ho P, Petersen PJ, Bradford PA, . Validation and reproducibility assessment of tigecycline MIC determinations by E-test. J Clin Microbiol 2007;45:2474–9.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005;49:3903.
   PubMed Web of Science ®Google Scholar
• British Society for Antimicrobial Chemotherapy website. Available at: http://www.bsac.org.uk (accessed 16 December 2010).
   Google Scholar
• Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother 2010;22:110–4.
   PubMed Web of Science ®Google Scholar
• British Society for Antimicrobial Chemotherapy Resistance Surveillance Project. Available at: http://www.bsacsurv.org (accessed 16 December 2010).
   Google Scholar
• Hope R, Mushtaq S, James D, Pilana T, Warner M, Livermore DM.Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK. J Antimicrob Chemother 2010; 65:26002–9.
   Web of Science ®Google Scholar
• Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int J Antimicrob Agents 2009; 34:121–30.
   PubMed Web of Science ®Google Scholar
• Claesson C, Nilsson LE, Kronvall G, Walder M, Sorberg M. Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals. Scand J Infect Dis 2009;41:171–81.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36:19–36.
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400–4.
   PubMed Web of Science ®Google Scholar
• Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008;30:2040–50.
   PubMed Web of Science ®Google Scholar
• Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65:288–99.
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009;33:130–6.
   PubMed Web of Science ®Google Scholar
• Kronvall G, Karlsson I, Sorberg M, Nilsson LE. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006;57:498–505.
   PubMed Web of Science ®Google Scholar